贝伐单抗联合吉非替尼片治疗非小细胞肺癌的临床研究

发布时间：2018-04-01 21:43

本文选题：贝伐单抗　切入点：吉非替尼片　出处：《中国临床药理学杂志》2017年08期

【摘要】：目的观察贝伐单抗联合吉非替尼片治疗非小细胞肺癌的临床疗效和安全性。方法将90例非小细胞肺癌患者随机分为对照组45例和试验组45例。对照组予以吉非替尼250 mg,qd,口服;试验组在对照组治疗的基础上,予以贝伐单抗7.5 mg·kg~(-1),qd,静脉滴注。2组患者一个疗程均为21 d,共治疗3个疗程。观察2组患者的临床疗效、血管内皮细胞生长因子(VEGF)及其受体(KDR)、基质金属蛋白酶-9(MMP-9)、上皮型黏附素(E-cad)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为77.78%(35/45例)和57.78%(26/45例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的VEGF分别为(0.76±0.08),(1.47±0.11);KDR分别为(0.65±0.13),(0.81±0.14);MMP-9分别为(0.87±0.15),(1.11±0.15);E-cad分别为(1.58±0.16),(1.32±0.14),差异均有统计学意义(均P0.05)。试验组的药物不良反应主要为皮疹、腹泻、头痛,对照组的药物不良反应主要为皮疹、腹泻,试验组和对照组的药物不良反应发生率分别为22.22%和15.56%,差异无统计学意义(P0.05)。结论贝伐单抗联合吉非替尼片治疗非小细胞肺癌具有较好的临床疗效,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of bevacizumab combined with gefitinib in the treatment of non-small cell lung cancer (NSCLC). Methods 90 patients with NSCLC were randomly divided into control group (n = 45) and experimental group (n = 45). The trial group was treated with bevacizumab 7.5 mg / kg ~ (-1) QD on the basis of the control group. The patients in group 2 received intravenous drip for 21 days for 3 courses of treatment. The clinical efficacy of the two groups was observed. The levels of vascular endothelial growth factor (VEGF) and its receptor (KDRN), matrix metalloproteinase-9 (MMP-9), epithelial adhesion factor (E-cad), and the occurrence of adverse drug reactions were observed. The total effective rates of the test group and the control group were 77.78 / 35 / 45 and 57.78 / 26 / 45, respectively. The difference was statistically significant (P 0.05). The VEGF of the test group and the control group were 0.76 卤0.08, 1.47 卤0.11, respectively, and the VEGF of the test group was 0.65 卤0.13, the MMP-9 was 0.87 卤0.15, E-cad was 1.58 卤0.161.32 卤0.14, the difference was statistically significant (P 0.05). The main adverse drug reactions in the test group were rash, diarrhea, headache, and the adverse drug reactions in the control group were mainly skin rash. The incidence of adverse drug reactions in the experimental group and control group were 22.22% and 15.56, respectively, with no significant difference (P 0.05). Conclusion Bevacumab combined with gefitinib has a better clinical effect in the treatment of non-small cell lung cancer. The incidence of adverse drug reactions was not increased.
【作者单位】：鄞州人民医院肿瘤放化疗中心;
【基金】：宁波市自然科学基金资助项目(2012A610199)
【分类号】：R734.2

【相似文献】